machen. VITX gibts auch. Allerdings ist Bio-Rad Laboratories Weltmarktführer in dem Bereich, Kürzel BIO.
f.h. testet diese Woche RBIO im Wettbewerb an.
Gruss E.
Rapid Bio Tests Announces Mad Cow Test and Treatment
SPRINGFIELD, Ore., Jan 9, 2004 (BUSINESS WIRE) -- Rapid Bio Tests
Corporation(RBIO), reports that it has been conducting feasibility studies
related to Bovine Spongiform Encephalopathy or Mad Cow Disease (BSE). The
company has taken this initiative in response to the confirmation of a
slaughtered dairy cow, testing positive for the disease, on December 23, 2003 in
Mabton, Washington.
Rapid Bio Tests Corporation has determined that the level of testing presently
conducted, in North America, to establish the presence of BSE is inadequate and
that the present system of limited testing of slaughtered animals presents a
risk of infected meat reaching the food chain because of it. At present, of the
37 million cattle slaughtered annually in the United States a small percentage
representing approximately 0.05 percent or 20,000, animals are actually tested.
In contrast, European nations last year tested 19 million cattle with 4200 cases
of Mad Cow Disease detected. In Japan, every cow headed for the dinner table is
tested for the disease, which represented approximately 1.2 million cattle last
year. Present day testing in North America is slow, with the recent case in
Mabton, Washington taking 13 days to complete.
The company's initiative is focused in two areas, that being it's ability to
develop a rapid diagnostic test for the purpose of establishing the presence of
Mad Cow Disease in "live" animals and in humans and secondly the company's
ability to develop an effective procedure to treat the disease or slow it down.
Rapid Bio Tests Corporation studies indicate that it has the capabilities to
develop a rapid diagnostic test using its existing technology platforms,
proprietary knowledge and present scientific research personnel. The company
further believes that it will be able to develop a procedure to test for the
presence of BSE in "live animals as well as humans," with results in less than
30 minutes without the need for a laboratory setting or experienced technicians.
The company further believes that it has identified ways of blocking infective
prion transport to the brain, thereby preventing the development of the disease
in both animals and humans.
Presently the company is continuing to conduct feasibility studies on both of
these initiatives with the primary consideration being the company's ability to
finance the research and development of the test and the treatment.
Consideration will be given to financing the projects internally or to jointly
proceeding with an industry partner if necessary. The company is presently
conducting additional scientific study to determine product viability and from
there it will determine if the necessary funding can be put in place to proceed.
About Rapid Bio Tests Corporation
Rapid Bio Tests Corporation is a diagnostics company, which has developed rapid
diagnostic testing technology platforms, that will be used for the development
and manufacturing of an array of rapid diagnostic tests. These tests will not
require instrumentation or electricity, will be simple to use in the field or
office, and will only require a few minutes to produce a result. The initial
tests that the corporation is proposing to develop include; West Nile Virus,
Hepatitis B, HIV 1 and 2, Tuberculosis, Bubonic Plague and the four strains of
Malaria.
"Safe Harbor" Statement: Certain statements in this release are
"forward-looking" statements as defined in the Private Securities Litigation
Reform Act of 1995. Such statements are subject to numerous risks and
uncertainties. Actual results may vary significantly from the results expressed
or implied in such statements. Factors that could cause actual results to
materially differ from forward-looking statements include, but are not limited
to, the Company's ability to meet the terms and conditions required to obtain
its project financing, risks and delays associated with product development,
risk of market acceptance of new products, risk of technology or product
obsolescence, competitive risks, reliance on development partners and the need
for additional capital.
SOURCE: Rapid Bio Tests Corporation
CONTACT: Rapid Bio Tests Corporation
Dr. Geoffrey Seaman, 541-686-5989
fax, 503-296-5990
www@rapidbiotests.com
|
Thread abonnieren
